Granada Perea
Radboud University Nijmegen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Granada Perea.
Leukemia | 2006
Granada Perea; Adriana Lasa; Anna Aventin; Alicia Domingo; Neus Villamor; M Paz Queipo de Llano; Andreu Llorente; Jordi Juncà; C. Palacios; Cristalina Fernández; M. Gallart; Llorens Font; M. Tormo; Lourdes Florensa; Joan Bargay; Josep-Maria Marti; Pilar Vivancos; Pio Torres; Juan Berlanga; I Badell; Salut Brunet; Jorge Sierra; Josep Nomdedeu
Most patients with acute myeloid leukemia (AML) and t(8;21) or inv(16) have a good prognosis with current anthracycline- and cytarabine-based protocols. Tandem analysis with flow cytometry (FC) and real-time RT-PCR (RQ-PCR) was applied to 55 patients, 28 harboring a t(8;21) and 27 an inv(16), including one case with a novel CBFbeta/MYH11 transcript. A total of 31% (n=17) of CR patients relapsed: seven with t(8;21) and 10 with inv(16). The mean amount of minimal residual disease (MRD) detected by FC in relapsed and nonrelapsed patients was markedly different: 0.3 vs 0.08% (P=0.002) at the end of treatment. The mean number of fusion transcript copies/ABLx104 also differed between relapsed and non-relapsed patients: 2385 vs 122 (P=0.001) after induction, 56 vs 7.6 after intensification (P=0.0001) and 75 vs 3.3 (P=0.0001) at the end of chemotherapy. Relapses were more common in patients with FC MRD level >0.1% at the end of treatment than in patients with ⩽0.1%: cumulative incidence of relapse (CIR) was 67 and 21% (P=0.03), respectively. Likewise, using RQ-PCR, a cutoff level of >10 copies at the end of treatment correlated with a high risk of relapse: CIR was 75% for patients with RQ-PCR >10 compared to 21% for patients with RQ-PCR levels ⩽10 (P=0.04). Combined use of FC and RQ-PCR may improve MRD detection, and provide useful clinical information on relapse kinetics in AML patients.
The American Journal of Surgical Pathology | 2012
Antonio Martínez; Maurilio Ponzoni; Claudio Agostinelli; Konnie M. Hebeda; Estella Matutes; Jacopo Peccatori; Cristina Campidelli; Blanca Espinet; Granada Perea; Agustín Acevedo; Ali Zare Mehrjardi; Monica Martinez-Bernal; Marta Gelemur; Emanuele Zucca; Stefano Pileri; Elias Campo; Armando López-Guillermo; María Rozman
Bone marrow involvement by lymphoma is considered a systemic dissemination of the disease arising elsewhere, although some tumors may arise primarily in the bone marrow microenvironment. Primary bone marrow lymphoma (PBML) is a rare entity whose real boundaries and clinicobiological significance are not well defined. Criteria to diagnose PBML encompass isolated bone marrow infiltration, with no evidence of nodal or extranodal involvement, including the bone, and the exclusion of leukemia/lymphomas that are considered to primarily involve the bone marrow. Twenty-one out of 40 lymphomas retrospectively reviewed by the International Extranodal Lymphoma Study Group from 12 institutions in 7 different countries over a 25-year period fulfilled the inclusion criteria. These cases comprised 4 follicular lymphomas (FLs), 15 diffuse large B-cell lymphomas (DLBCLs), and 2 peripheral T-cell lymphomas, not otherwise specified. The FL cases showed paratrabecular infiltration, BCL2 protein and CD10 expression, and BCL2 gene rearrangement. DLBCL showed nodular infiltration in 6 cases and was diffuse in 9 cases; it also showed positivity for BCL2 protein (9/10) and IRF4 (6/8). Median age was 65 years with male predominance. All but 3 FL patients were symptomatic. Most cases presented with cytopenias and high lactate dehydrogenase. Four patients (3 FL cases and 1 DLBCL case) had leukemic involvement. Most DLBCL patients received CHOP-like or R-CHOP-like regimens. The outcome was unfavorable, with a median overall survival of 1.8 years. In conclusion, PBML is a very uncommon lymphoma with particular clinical features and heterogenous histology. Its recognition is important to establish accurate diagnosis and adequate therapy.
Medicina Clinica | 2011
Lourdes Florensa; José Tomás Navarro; María Encarnación Pérez Vila; Alicia Domingo; Esmeralda de la Banda; María Rozman; Mireia Camós; Fuensanta Millá; Granada Perea; Esther Alonso; Ramon Ayats; Ana Aventin; Elena Cabezudo; Blanca Espinet; Ana Merino; Pilar Romero; Carmen Sánchez; Esperanza Tuset; Francesc Solé; Evarist Feliu; Cristalina Fernández; Miquel Gallart; Teresa Vallespi; Soledad Woessner
BACKGROUND AND OBJECTIVES Persistent polyclonal B-cell lymphocytosis (PPBL) is a rare entity, presenting especially in adult smoker women. It is characterized by an increase of serum IgM, DR7-HLA haplotype, cytogenetic abnormalities and multiple IgH/BCL-2 rearrangements. To date, it has not been elucidated whether this is a benign or premalignant disorder. We analyzed the PPBL characteristics with especial attention to its evolution. PATIENTS AND METHODS Thirty-five PPBL patients from 5 hospitals in Catalonia were retrospectively analyzed. A simultaneous morphologic review of the blood smears was performed by members of the GCCH in a 16 multiple-observer optic microscope. Clinical and biological data were also analyzed. RESULTS PPBL presents in the majority of cases with persistent polyclonal B-cell lymphocytosis and affects primarily smoker women. The morphologic hallmark, in absence of viral infections, is the presence of activated lymphocytes with bilobulated and/or cleaved nuclei, and nuclear pockets in the ultrastructural study. Increased serum IgM, HLA-DR7 haplotype, chromosomal abnormalities such as i(3)(q10) and multiple IgH/BCL-2 rearrangements were detected. Thirty-four out of 35 patients are alive after a median follow up of 70.7 months. One patient died because of lung adenocarcinoma and another developed a follicular lymphoma without relation to PPBL. CONCLUSIONS PPBL has an asymptomatic and stable evolution, although it frequently presents genetic abnormalities. It remains unknown whether it is a premalignant entity, similar to monoclonal gammopathies of unknown significance. Hence, accurate cytologic diagnosis and follow-up are essential.
American Journal of Clinical Pathology | 2002
Mar Bellido; Enriqueta Rubiol; Josep Ubeda; Camino Estivill; Granada Perea; Joana Rego-Araujo; Anna Aventin; Ramon Bordes; Jorge Sierra; Josep Nomdedeu
Patients with mature follicular B-cell lymphomas develop aggressive non-Hodgkin lymphomas (NHLs) during disease progression. It is controversial whether most diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphomas (BLs) emerge as de novo lymphomas or from an original follicular lymphoma. To distinguish clonally related populations in aggressive NHL, we studied the immunophenotypic features of 18 consecutive samples from 16 patients. Three flow cytometric patterns were distinguished: (1) a homogeneous neoplastic population of large B cells with phenotypic features of follicular center cells; (2) 2 atypical populations of B cells, small monoclonal B cells, and large B cells with loss of some surface antigens; and (3) 2 clonal populations of small and large B cells sharing the same light-chain isotype. The 3 flow cytometric patterns were observed, respectively, in de novo DLBCL and BL, transformation into BL, and transformation into DLBCL. Flow cytometric data can provide valuable information about the natural history of NHL.
Hematological Oncology | 2017
Josep Nomdedeu; Eulàlia Puigdecanet; Elena Bussaglia; Juan José Hernández; Maite Carricondo; Camino Estivill; Josep M. Martí-Tutusaus; Mar Tormo; Lurdes Zamora; Elena Serrano; Granada Perea; Maria Paz Queipo de Llano; Antoni Garcia; Isabel Sánchez-Ortega; Josep Maria Ribera; Lara Nonell; Anna Aventin; Francesc Solé; Maria Salut Brunet; Jorge Sierra
Deoxyribonucleic acid microarrays allow researchers to measure mRNA levels of thousands of genes in a single experiment and could be useful for diagnostic purposes in patients with acute myeloid leukaemia (AML). We assessed the feasibility of the AML profiler (Skyline™ Array) in genetic stratification of patients with de novo AML and compared the results with those obtained using the standard cytogenetic and molecular approach.
Blood | 2006
Mariano Monzo; Salut Brunet; Alvaro Urbano-Ispizua; Alfons Navarro; Granada Perea; Jordi Esteve; Rosa Artells; Miquel Granell; Juan Berlanga; Josep Maria Ribera; Javier Bueno; Andreu Llorente; Ramon Guardia; Mar Tormo; Pio Torres; Josep Nomdedeu; Emili Montserrat; Jordi Sierra
Annals of Oncology | 2004
Silvia Montoto; Armando López-Guillermo; Albert Altés; Granada Perea; Ana Ferrer; Mireia Camós; Luís Villela; Francesc Bosch; Jordi Esteve; Francisco Cervantes; Joan Bladé; Benet Nomdedeu; Elias Campo; Jorge Sierra; Emilio Montserrat
Annals of Oncology | 2005
Granada Perea; Albert Altés; Silvia Montoto; Armando López-Guillermo; Eva Domingo-Domenech; A. Fernández-Sevilla; Josep Maria Ribera; Javier Grau; Carmen Pedro; J. Angel Hernández; Cristina Estany; Javier Briones; Rodrigo Martino; Anna Sureda; Jorge Sierra; Emilio Montserrat
Haematologica | 2000
Elena Rámila; Anna Sureda; Rodrigo Martino; Amparo Santamaría; Tomás Franquet; Carmen Puzo; Jesus Montesinos; Granada Perea; Jorge Sierra
Haematologica | 2002
Rodrigo Martino; Granada Perea; Caballero; M.V. Mateos; Josep Maria Ribera; Jp de Oteyza; Reyes Arranz; Mj Terol; Jorge Sierra; J. F. San Miguel